Samsung Biologics Co.,Ltd. (207940.KS)

KRW 959000.0

(-2.14%)

Market Cap (In KRW)

68255.86 Billion

Revenue (In KRW)

3694.58 Billion

Net Income (In KRW)

857.69 Billion

Avg. Volume

123.64 Thousand

Currency
KRW
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
707000.0-1113000.0
PE
-
EPS
-
Beta Value
0.323
ISIN
KR7207940008
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. John Chongbo Rim
Employee Count
-
Website
https://samsungbiologics.com
Ipo Date
2016-11-11
Details
Samsung Biologics Co.,Ltd. engages in the contract manufacturing organization (CMO) business for biopharmaceuticals products. The company operates in two segments, CMO and Contract Development Organization (CDO). It is involved in the provision of CDO services, including cell line development, upstream and downstream processes, and analytical methods and formulations. The company also offers aseptic filling, lyophilization, finishing, storage and shipping, and support services; and quality assurance and control, as well as biosafety and analytical testing services. In addition, it engages in the development and commercialization of biosimilar drugs; and manufactures mammalian cell-based antibody drugs. The company was founded in 2011 and is headquartered in Incheon, South Korea.